Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms- |
Action inhibitors |
Mechanism CDK2 inhibitors(Cyclin-dependent kinase 2 inhibitors), CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK5 inhibitors(Cyclin-dependent kinase 5 inhibitors) + [1] |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC40H47BrFN9O9S |
InChIKeyRVBRYNIJOYPZIA-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | United States | 03 Jun 2020 | |
Ovarian Cancer | Preclinical | United States | 03 Jun 2020 |